Table 3 Correlation between PIK3CA mutation status and clinical variables
From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
PIK3CA wild-type | PIK3CA mutated | P valuea | ||
|---|---|---|---|---|
Pathological complete response (pCR) versus residual disease (RD) | RD | 95 (83%) | 18 (82%) | 1.000 |
pCR | 20 (17%) | 4 (18%) | ||
Unknown | 2 | 1 | - | |
Residual cancer burden | 0 | 20 (22.0%) | 4 (26.7%) | 0.121 (0.166b) |
I | 7 (7.7%) | 0 (0%) | ||
II | 37 (40.7%) | 10 (66.7%) | ||
III | 27 (29.7%) | 1 (6.7%) | ||
Unknown | 26 | 8 | - | |
Estrogen receptor (ER) status | ER- | 54 (46%) | 8 (35%) | 0.365 |
ER+ | 63 (54%) | 15 (65%) | ||
Progesterone receptor (PR) status | PR- | 71 (60.7%) | 11 (47,8%) | 0.259 |
PR+ | 46 (39.3) | 12 (52,2%) | ||
HER2 status | HER2- | 104 (89%) | 21 (91%) | 1.000 |
HER2+ | 13 (11%) | 2 (9%) | ||
Grade | Grade 1–2 | 46 (47%) | 10 (56%) | 0.612 |
Grade 3 | 51 (53%) | 8 (44%) | ||
Unknown | 20 | 5 | - | |
Nodal status | Negative | 29 (25%) | 12 (52%) | 0.012 |
Positive | 88 (75%) | 11 (48%) | ||
Tumor size | T0 | 1 (1%) | 1 (4%) | 0.535 |
T1 | 7 (6%) | 0 (0%) | ||
T2 | 59 (50%) | 12 (52%) | ||
T3 | 18 (15%) | 3 (13%) | ||
T4 | 32 (27%) | 7 (30%) | ||
Ethnicity | Asian | 2 (2%) | 1 (4%) | 0.505 |
Black | 11 (9%) | 2 (9%) | ||
Hispanic | 40 (34%) | 10 (43%) | ||
Caucasian | 64 (55%) | 10 (43%) | ||
Median age (minimum-maximum), years | 50 (28–73) | 52 (42–73) | - |